I den farmakokinetiske populationsanalyse blev det skønnet, at ranolazineksponering hos forsøgspersoner med moderat nedsat nyrefunktion (kreatininclearance 40 ml/ min) steg 1, 2 gange.
In the population pharmacokinetic analysis, a 1.2-fold increase in ranolazine exposure was estimated in subjects with moderate impairment (creatinine clearance 40 ml/ min).